ERBB2 and neoplasm: Concerning local recurrences, HER2-negative tumours which gave rise to HER2-low recurrences relapsed significantly later than tumours with stable HER2 expression (101.3 ± 61.4 versus 66.9 ± 54.8 months; P = 0.013) and tended to appear in younger patients (52.4 ± 11.8 versus 60.8 ± 17.1 years), even though these differences were not statistically significant (P = 0.057).